Corient Private Wealth
SUPN icon

Corient Private Wealth’s Supernus Pharmaceuticals SUPN Stock Holding History

Corient Private Wealth’s Portfolio SUPN Stock Details SUPN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$250K Sell
4,842
-4,692
-49% -$239K ﹤0.01% 2423
2025
Q4 		$474K Buy
+9,534
New +$464K ﹤0.01% 2351

Other funds holding SUPN

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
NAMI
Nomura Asset Management International Philadelphia, Pennsylvania $58.4B AUM
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Corient Private Wealth's SUPN Position: Q1 2026 in Review

Corient Private Wealth reduced its Supernus Pharmaceuticals (SUPN) stake by 49% in Q1 2026, selling an estimated $239K and leaving 4,842 shares worth $250K. The position accounts for ﹤0.01% of the portfolio, ranked #2423.

Corient Private Wealth first reported a position in SUPN in Q4 2025 and has held it in 2 quarters since. The position peaked at $474K in Q4 2025. 327 funds tracked by Wall St. Rank hold SUPN as of Q1 2026.

  • Corient Private Wealth held 4,842 shares of Supernus Pharmaceuticals worth $250K as of Q1 2026.
  • Corient Private Wealth sold 4,692 Supernus Pharmaceuticals shares in Q1 2026, an estimated $239K.
  • Supernus Pharmaceuticals made up ﹤0.01% of Corient Private Wealth's portfolio in Q1 2026, its #2423 holding.
  • Corient Private Wealth first reported a position in Supernus Pharmaceuticals in Q4 2025 and has held it in 2 quarters since.
  • Corient Private Wealth's Supernus Pharmaceuticals position peaked at $474K in Q4 2025.
  • 327 funds tracked by Wall St. Rank held Supernus Pharmaceuticals as of Q1 2026.

Based on Corient Private Wealth's 13F filing for Q1 2026, filed 15 May 2026.